Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2016 - 2026)

Corvus Pharmaceuticals' Income towards Parent Company history spans 12 years, with the latest figure at -$13.1 million for Q1 2026.

  • Quarterly Income towards Parent Company fell 183.23% to -$13.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$42.2 million through Mar 2026, down 12.62% year-over-year, with the annual reading at -$13.3 million for FY2025, 77.45% up from the prior year.
  • Income towards Parent Company came in at -$13.1 million for Q1 2026, down from -$11.6 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $15.7 million in Q1 2025 to a low of -$39.5 million in Q3 2024.
  • The 5-year median for Income towards Parent Company is -$7.0 million (2022), against an average of -$8.2 million.
  • Year-over-year, Income towards Parent Company plummeted 669.91% in 2024 and then skyrocketed 364.98% in 2025.
  • Corvus Pharmaceuticals' Income towards Parent Company stood at -$5.7 million in 2022, then grew by 7.36% to -$5.2 million in 2023, then plummeted by 89.35% to -$9.9 million in 2024, then fell by 16.85% to -$11.6 million in 2025, then decreased by 12.73% to -$13.1 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Income towards Parent Company are -$13.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$9.8 million (Q3 2025).